Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 1 |
2021 | 1 |
2024 | 3 |
Search Results
4 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer.
Cancer Immunol Res. 2024 Apr 1:OF1-OF12. doi: 10.1158/2326-6066.CIR-23-0638. Online ahead of print.
Cancer Immunol Res. 2024.
PMID: 38563577
Rapid Generation of Murine Bispecific Antibodies Using FAST-IgTM for Preclinical Screening of HER2/CD3 T-Cell Engagers.
Koga H, Kuroi H, Hirano R, Hirayama H, Nabuchi Y, Kuramochi T.
Koga H, et al. Among authors: kuroi h.
Antibodies (Basel). 2024 Jan 2;13(1):3. doi: 10.3390/antib13010003.
Antibodies (Basel). 2024.
PMID: 38247567
Free PMC article.
Item in Clipboard
Engineering CD3/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small cell lung cancer.
Mikami H, Feng S, Matsuda Y, Ishii S, Naoi S, Azuma Y, Nagano H, Asanuma K, Kayukawa Y, Tsunenari T, Kamikawaji S, Iwabuchi R, Shinozuka J, Yamazaki M, Kuroi H, Ho SSW, Gan SW, Chichili P, Pang CL, Yeo CY, Shimizu S, Hironiwa N, Kinoshita Y, Shimizu Y, Sakamoto A, Muraoka M, Takahashi N, Kawa T, Shiraiwa H, Mimoto F, Kashima K, Kamata-Sakurai M, Ishikawa S, Aburatani H, Kitazawa T, Igawa T.
Mikami H, et al. Among authors: kuroi h.
Cancer Immunol Res. 2024 Mar 20. doi: 10.1158/2326-6066.CIR-23-0638. Online ahead of print.
Cancer Immunol Res. 2024.
PMID: 38558120
Item in Clipboard
Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation.
Kamata-Sakurai M, Narita Y, Hori Y, Nemoto T, Uchikawa R, Honda M, Hironiwa N, Taniguchi K, Shida-Kawazoe M, Metsugi S, Miyazaki T, Wada NA, Ohte Y, Shimizu S, Mikami H, Tachibana T, Ono N, Adachi K, Sakiyama T, Matsushita T, Kadono S, Komatsu SI, Sakamoto A, Horikawa S, Hirako A, Hamada K, Naoi S, Savory N, Satoh Y, Sato M, Noguchi Y, Shinozuka J, Kuroi H, Ito A, Wakabayashi T, Kamimura M, Isomura F, Tomii Y, Sawada N, Kato A, Ueda O, Nakanishi Y, Endo M, Jishage KI, Kawabe Y, Kitazawa T, Igawa T.
Kamata-Sakurai M, et al. Among authors: kuroi h.
Cancer Discov. 2021 Jan;11(1):158-175. doi: 10.1158/2159-8290.CD-20-0328. Epub 2020 Aug 25.
Cancer Discov. 2021.
PMID: 32847940
Item in Clipboard
Cite
Cite